The Lancet HIV in conversation with
Jul 27, 2026 · 23 min · 12 segments
Living longer with HIV is one of medicine's greatest success stories, but longevity brings new challenges. By 2040, more than half of all people living with HIV are expected to be over the age of 50…
Kerry AlthoffGuest
Amy JusticeGuest
Adrian Gonzalez-LopezHostThis commission is not only discussed here today, but it's also being officially launched on July 28th at a satellite session at the IAS annual conference in Rio de Janeiro.
The commission will be also free to access in our website for everyone that wants to enjoy it.
Before we get into our guest, and as always, I would like to draw your attention to a couple of other pieces in this mass issue.
First, we have the RIO trial, a placebo-controlled randomized control trial providing data on time of HIV rebound after infusion of a mix of long-acting broadly neutralizing antibodies followed by an analytical treatment interaction phase.
Also in this issue, we have the artistry trial, offering safety and efficacy data of switching to oral Victagravir, Lenacapavir regime versus continuing Victagravir, MC-Tetravir, and Tenofovir, Lafenamid, in virological suppressed people with HIV.
And finally, and related to the commission itself, please do not miss, two linked comments discussing educational needs of caregivers of people aging with HIV in low-income, middle-income, and high-income settings.
This commission is not only discussed here today, but it's also being officially launched on July 28th at a satellite session at the IAS annual conference in Rio de Janeiro.
The commission will be also free to access in our website for everyone that wants to enjoy it.
Before we get into our guest, and as always, I would like to draw your attention to a couple of other pieces in this mass issue.
First, we have the RIO trial, a placebo-controlled randomized control trial providing data on time of HIV rebound after infusion of a mix of long-acting broadly neutralizing antibodies followed by an analytical treatment interaction phase.
Also in this issue, we have the artistry trial, offering safety and efficacy data of switching to oral Victagravir, Lenacapavir regime versus continuing Victagravir, MC-Tetravir, and Tenofovir, Lafenamid, in virological suppressed people with HIV.
And finally, and related to the commission itself, please do not miss, two linked comments discussing educational needs of caregivers of people aging with HIV in low-income, middle-income, and high-income settings.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
